<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Doklady Biological Sciences</journal-id><journal-title-group><journal-title xml:lang="en">Doklady Biological Sciences</journal-title><trans-title-group xml:lang="ru"><trans-title>Доклады Российской академии наук. Науки о жизни</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2686-7389</issn><issn publication-format="electronic">3034-5057</issn><publisher><publisher-name xml:lang="en">The Russian Academy of Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">684012</article-id><article-id pub-id-type="doi">10.31857/S2686738925020109</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Modular nanotransporters containing Keap1 monobodies are capable of reducing the toxic effect of acetaminophen on the liver of mice</article-title><trans-title-group xml:lang="ru"><trans-title>Модульные нанотранспортеры, содержащие монободи к Keap1, способны уменьшать токсическое действие парацетамола на печень мышей</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Khramtsov</surname><given-names>Y. V.</given-names></name><name xml:lang="ru"><surname>Храмцов</surname><given-names>Ю. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alsobolev@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Rosenkranz</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Розенкранц</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alsobolev@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ulasov</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Уласов</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alsobolev@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Slastnikova</surname><given-names>T. А.</given-names></name><name xml:lang="ru"><surname>Сластникова</surname><given-names>Т. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alsobolev@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Lupanova</surname><given-names>T. N.</given-names></name><name xml:lang="ru"><surname>Лупанова</surname><given-names>Т. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alsobolev@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Alieva</surname><given-names>R. T.</given-names></name><name xml:lang="ru"><surname>Алиева</surname><given-names>Р. Т.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alsobolev@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Georgiev</surname><given-names>G. P.</given-names></name><name xml:lang="ru"><surname>Георгиев</surname><given-names>Г. П.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Academician of the RAS</p></bio><bio xml:lang="ru"><p>академик РАН</p></bio><email>alsobolev@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sobolev</surname><given-names>A. S.</given-names></name><name xml:lang="ru"><surname>Соболев</surname><given-names>А. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alsobolev@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Institute of Gene Biology, RAS</institution></aff><aff><institution xml:lang="ru">Институт биологии гена Российской академии наук</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Lomonosov Moscow State University Moscow</institution></aff><aff><institution xml:lang="ru">Московский государственный университет им. М.В. Ломоносова</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-04-15" publication-format="electronic"><day>15</day><month>04</month><year>2025</year></pub-date><volume>521</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>225</fpage><lpage>228</lpage><history><date date-type="received" iso-8601-date="2025-06-11"><day>11</day><month>06</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-06-11"><day>11</day><month>06</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Russian Academy of Sciences</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Российская академия наук</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Russian Academy of Sciences</copyright-holder><copyright-holder xml:lang="ru">Российская академия наук</copyright-holder></permissions><self-uri xlink:href="https://journals.eco-vector.com/2686-7389/article/view/684012">https://journals.eco-vector.com/2686-7389/article/view/684012</self-uri><abstract xml:lang="en"><p>Previously, we created a modular nanotransporter (MNT) containing a monobody to Keap1, an intracellular protein inhibitor of the Nrf2 transcription factor that controls cellular protection from oxidative stress and is capable of interacting with Keap1 in hepatocytes and protect this cells from the effects of hydrogen peroxide. Oxidative liver damage by acetaminophen was used as a model to study the antitoxic effect of this MNT. Intraperitoneal injection of acetaminophen to mice resulted in an increase in the level of alanine aminotransferase and aspartate aminotransferase in the blood, as well as in liver edema. A significant decrease in the level of these enzymes in the blood, along with a decrease in liver edema, was observed after preliminary intravenous administration of MNT 2 hours before the acetaminophen injection. The results obtained can serve as a basis for creating drugs aimed at treating diseases associated with oxidative stress.</p></abstract><trans-abstract xml:lang="ru"><p>Ранее нами был создан модульный нанотранспортер (МНТ), содержащий монободи к Keap1 – внутриклеточному белку-ингибитору фактора транскрипции Nrf2, контролирующего защиту клеток от окислительного стресса, и способный в гепатоцитах взаимодействовать с Keap1 и защищать эти клетки от действия перекиси водорода. В качестве модели для исследования противотоксического действия данного МНТ использовали окислительное повреждение печени парацетамолом. Внутрибрюшинная инъекция мышам парацетамола приводила к повышению уровня аланинаминотрансфразы и аспартатаминотрансферазы в крови, а также к отеку печени. Значительное снижение уровня этих ферментов в крови, наряду с уменьшением отека печени, наблюдалось после предварительного внутривенного введения МНТ за 2 часа до инъекции парацетамола. Полученные результаты могут послужить основой для создания препаратов, направленных на лечение болезней, связанных с окислительным стрессом.</p></trans-abstract><kwd-group xml:lang="en"><kwd>modular nanotransporters</kwd><kwd>monobodies</kwd><kwd>Nrf2</kwd><kwd>Keap1</kwd><kwd>acetaminophen</kwd><kwd>ALT</kwd><kwd>AST</kwd><kwd>single-photon emission computed tomography</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>модульные нанотранспортеры</kwd><kwd>монободи</kwd><kwd>Nrf2</kwd><kwd>Keap1</kwd><kwd>парацетамол</kwd><kwd>АЛТ</kwd><kwd>АСТ</kwd><kwd>однофотонная эмиссионная компьютерная томография</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="ru">Российский научный фонд</institution></institution-wrap><institution-wrap><institution xml:lang="en">Russian Science Foundation</institution></institution-wrap></funding-source><award-id>24-14-00170</award-id></award-group></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Bellezza I., Giambanco I., Minelli A., et al. // Acta Mol. Cell Res. 2018. V. 1865(5). P. 721–733.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Hayes J.D., Dinkova-Kostova A.T. // Trends Biochem. Sci. 2014. V. 39(4). P. 199–218.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Ulasov A.V., Rosenkranz A.A., Georgiev G.P., et al. // Life Sci. 2022. V. 291. 120111.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Robledinos-Anton N., Fernandez-Gines R., Manda G., et al. // Oxid. Med. Cell Longev. 2019. V. 2019. 9372182.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Ngo V., Duennwald M.L. // Antioxidants. (Basel). 2022. V. 11(12).</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Taguchi K., Kensler T.W. // Arch. Pharm. Res. 2020. V. 43(3). P. 337–349.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Patra U., Mukhopadhyay U., Sarkar R., et al. // Antivir. Res. 2019. V. 161. P. 53–62.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Olagnier D., Farahani E., Thyrsted J., et al. // Nat. Commun. 2020. V. 11. 4938.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Khramtsov Y.V., Ulasov A.V., Slastnikova T.A., et al. // Pharmaceutics. 2023. V. 15. 2687.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Khramtsov Y.V., Ulasov A.V., Rosenkranz A.A., et al. // Pharmaceutics. 2024. V. 16. 1345.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Lee W.M. // Hepatol. 2017. V. 67. P. 1324–1331.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>McGill M.R., Williams C.D., Xie Y., et al. // Toxicol. Appl. Pharmacol. 2012. V. 264. P. 387–394.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Vorobyeva A., Bragina O., Altai M., et al. // Contrast. Media Mol. Imaging. 2018. V. 2018. 6930425.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Steffens M. G., Kranenborg M.H., O.C. Boerman O.C., et al. // Cancer Biother. Radiopharm. 1998. V. 13. P. 133–139.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Ferris T., Carroll L., Jenner S., et al. // J. Labelled Comp Radiopharm. 2021. V. 64. P. 92–108.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Bruinstroop E., van der Spek A.H., Boelen A. // Eur. Thyroid J. 2023. V. 12. e220211.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Dohan O., De la Vieja A., Paroder V., et al. // Endocr. Rev. 2003. V. 24. P. 48–77.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Shen Z., Wang Y., Su Z., et al. // Chem. Biol. Interact. 2018. V. 282. P. 22–28.</mixed-citation></ref></ref-list></back></article>
